Protagonist Therapeutics (PTGX) Current Assets (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Current Assets of $613.5 million for Q1 2026, up 6.21% sequentially from $577.6 million in Q4 2025, and up 1.25% YoY from $605.9 million in Q1 2025.
Protagonist Therapeutics (PTGX) Current Assets (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Current Assets for 12 years, with the latest figure at $613.5 million in Q1 2026.
- Quarterly Current Assets rose 1.25% year-over-year to $613.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $613.5 million (up 1.25% YoY) and the FY2025 annual result came in at $577.6 million, down 2.38% from the prior year.
- Current Assets grew to $613.5 million in Q1 2026 per PTGX's latest filing, from $577.6 million in the prior quarter.
- Over five years, Current Assets peaked at $627.6 million in Q1 2024 and troughed at $235.7 million in Q1 2023.
- A 5-year average of $450.1 million and a median of $476.8 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets tumbled 30.97% in 2023, then surged 166.21% in 2024.
- Over 5 years, Current Assets stood at $243.1 million in 2022, then jumped by 46.28% to $355.6 million in 2023, then surged by 66.39% to $591.6 million in 2024, then declined by 2.38% to $577.6 million in 2025, then increased by 6.21% to $613.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $613.5 million, $577.6 million, and $586.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 807.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 807.15 Mn |
| Mar 31, 2026 | 613.46 Mn |
| Dec 31, 2025 | 577.57 Mn |
| Sep 30, 2025 | 586.42 Mn |
| Jun 30, 2025 | 602.53 Mn |
| Mar 31, 2025 | 605.86 Mn |
| Dec 31, 2024 | 591.64 Mn |
| Sep 30, 2024 | 476.77 Mn |
| Jun 30, 2024 | 570.93 Mn |
| Mar 31, 2024 | 627.55 Mn |
| Dec 31, 2023 | 355.58 Mn |
| Sep 30, 2023 | 324.88 Mn |
| Jun 30, 2023 | 316.94 Mn |
| Mar 31, 2023 | 235.74 Mn |
| Dec 31, 2022 | 243.08 Mn |
| Sep 30, 2022 | 276.62 Mn |
| Jun 30, 2022 | 304.30 Mn |
| Mar 31, 2022 | 341.52 Mn |
| Dec 31, 2021 | 340.74 Mn |
| Sep 30, 2021 | 327.69 Mn |